View in EDS HTML Full Text PDF Full Text

Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.

Saved in:
Bibliographic Details
Title: Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.
Authors: Savion Gaiger N; Medical Oncology, Yale School of Medicine, New Haven, CT, United States., Hurwitz ME; Medical Oncology, Yale School of Medicine, New Haven, CT, United States., Hafez N; Hematology Oncology, Cedars Sinai, Los Angeles, CA, United States., Kluger HM; Medical Oncology, Yale School of Medicine, New Haven, CT, United States., Herold KC; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Department of Immunobiology, Yale School of Medicine, New Haven, CT, United States., Perdigoto AL; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Department of Internal Medicine, Veterans Administration Hospital, West Haven, CT, United States.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 Nov 07; Vol. 16, pp. 1697724. Date of Electronic Publication: 2025 Nov 07 (Print Publication: 2025).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41282287
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Savion+Gaiger+N%22">Savion Gaiger N</searchLink>; Medical Oncology, Yale School of Medicine, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22Hurwitz+ME%22">Hurwitz ME</searchLink>; Medical Oncology, Yale School of Medicine, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22Hafez+N%22">Hafez N</searchLink>; Hematology Oncology, Cedars Sinai, Los Angeles, CA, United States.<br /><searchLink fieldCode="AU" term="%22Kluger+HM%22">Kluger HM</searchLink>; Medical Oncology, Yale School of Medicine, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22Herold+KC%22">Herold KC</searchLink>; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Department of Immunobiology, Yale School of Medicine, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22Perdigoto+AL%22">Perdigoto AL</searchLink>; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.; Department of Internal Medicine, Veterans Administration Hospital, West Haven, CT, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101555782%22">Frontiers in endocrinology</searchLink> [Front Endocrinol (Lausanne)] 2025 Nov 07; Vol. 16, pp. 1697724. <i>Date of Electronic Publication: </i>2025 Nov 07 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101555782 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1664-2392 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216642392%22">16642392 </searchLink><i>NLM ISO Abbreviation: </i>Front Endocrinol (Lausanne) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41282287
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fendo.2025.1697724
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1697724
    Titles:
      – TitleFull: Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Savion Gaiger N
      – PersonEntity:
          Name:
            NameFull: Hurwitz ME
      – PersonEntity:
          Name:
            NameFull: Hafez N
      – PersonEntity:
          Name:
            NameFull: Kluger HM
      – PersonEntity:
          Name:
            NameFull: Herold KC
      – PersonEntity:
          Name:
            NameFull: Perdigoto AL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 11
              Text: 2025 Nov 07
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 1664-2392
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in endocrinology
              Type: main
ResultId 1